Merck & Co., US58933Y1055

Merck & Co. stock: EU panel backs WELIREG combo

Published on 11/16/2026 at 16:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock is in focus after an EU panel backed WELIREG with lenvatinib for advanced kidney cancer. The Commission will decide next.

EU decision moves WELIREG forward

  • Merck said the CHMP recommendation covers adults with advanced clear cell renal cell carcinoma after anti-PD-1 or anti-PD-L1 treatment.
  • The European Commission will decide whether to grant marketing authorization in the European Union and several related markets.
  • Trial results showed a progression-free survival benefit, while overall survival did not reach statistical significance at final analysis.
Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck said on November 13 that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending WELIREG, or belzutifan, with lenvatinib for adults with advanced clear cell renal cell carcinoma after treatment with an anti-PD-1 or anti-PD-L1 therapy. The announcement was carried by StockTitan.

European approval remains ahead

The CHMP opinion is a recommendation rather than a final marketing authorization. The European Commission is expected to review the application, with a decision expected within two months, according to the release.

The proposed regimen combines Merck's WELIREG with Eisai's lenvatinib. If authorized, the combination would add a new treatment option for patients whose advanced kidney cancer has progressed after an anti-PD-1 or anti-PD-L1 therapy.

Phase 3 results support application

The recommendation followed results from the Phase 3 LITESPARK-011 study. WELIREG plus lenvatinib reduced the risk of disease progression or death by 26% versus cabozantinib, with a hazard ratio of 0.74 and a p-value of 0.001.

At final analysis, overall survival did not reach statistical significance. The combination nevertheless produced a 53.1% objective response rate versus 40.2% for cabozantinib, while median duration of response was 22.0 months versus 11.9 months.

Investors watch regulatory execution

The application adds a regulatory catalyst to Merck's oncology portfolio, but the final European decision remains the next material milestone. The commercial opportunity depends on the scope and timing of any authorization, as well as uptake in a competitive kidney-cancer market.

Merck & Co. stock traded at 135.06 euros on Lang & Schwarz at 16:15 CET on Monday, November 16, 2026, 1.89% above the Xetra close of Friday, November 13, 2026.

Merck & Co. stock at a glance

  • Company: Merck & Co., Inc.
  • ISIN: US58933Y1055
  • Home market: New York Stock Exchange
  • Price: 135.06 euros on Lang & Schwarz, November 16, 2026, 16:15 CET
  • Xetra close: 132.56 euros on November 13, 2026

US equities remain the broader market setting for Merck & Co. stock; see Current market reports.

More news and analyses on Merck & Co. stock

Disclaimer...
en | US58933Y1055 | MERCK & CO. | boerse | 70521567 | bgmi